ProGen (Drug Discovery) Overview
- Year Founded
-
1998
- Status
-
Public
- Employees
-
50
- Stock Symbol
-
296160
- Investments
-
1
- Share Price
-
$1.35
- (As of Thursday Closing)
ProGen (Drug Discovery) General Information
Description
Progen Co Ltd is an R&D focused biopharmaceutical development venture. It is engaged in developing metabolic disease treatments, immune disease treatments, and immune anti cancer drugs using its immunology based drug development know how, and is focusing on developing inventive drugs through domestic and international open innovation.
Contact Information
Website
www.progen.co.krCorporate Office
- 7th Floor, Bio Innovation Park
- 172, Magokjungang-ro, Gangseo-gu
- Seoul
- South Korea
Corporate Office
- 7th Floor, Bio Innovation Park
- 172, Magokjungang-ro, Gangseo-gu
- Seoul
- South Korea
ProGen (Drug Discovery) Stock Performance
As of 12-Nov-2026, ProGen (Drug Discovery)’s stock price is $1.35. Its current market cap is $19.1M.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.35 | $1.33 | $1.25 - $5.63 | $19.1M | 5.3K | -$0.98 |
ProGen (Drug Discovery) Financials Summary
As of 31-Dec-2025, ProGen (Drug Discovery) has a trailing 12-month revenue of $622K.
|
In Thousands, USD |
TTM 31-Dec-2025 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 114,877 | 114,877 | 75,918 | |
| Revenue | 622 | 622 | 500 | 845 |
| EBITDA | (10,423) | (10,423) | (836) | 10,241 |
| Net Income | (14,118) | (14,118) | (4,144) | 6,857 |
| Total Assets | 118,478 | 118,478 | 92,095 | 94,115 |
| Total Debt | 62,165 | 62,165 | 38,427 | 33,392 |
ProGen (Drug Discovery) Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
ProGen (Drug Discovery) Patents
ProGen (Drug Discovery) Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026206803-A1 | Bispecific glp-1ra/glp-2ra fusion protein dosage forms and methods | Pending | 24-Mar-2025 | ||
| WO-2026151313-A1 | Bispecific protein comprising anti-actrii antibody and anti-myostatin antibody and uses thereof | Pending | 10-Jan-2025 | ||
| WO-2024144336-A1 | Novel bispecific fusion protein and use thereof | Inactive | 30-Dec-2022 | ||
| WO-2022149881-A1 | Novel cell line for producing il-10 variant fusion protein and use thereof | Inactive | 07-Jan-2021 | ||
| WO-2021230705-A1 | Novel recombinant fusion protein and use thereof | Inactive | 14-May-2020 | C07K14/605 |
ProGen (Drug Discovery) Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
ProGen (Drug Discovery) Investments (1)
ProGen (Drug Discovery)’s most recent deal was a PIPE with Genexine for . The deal was made on 15-Jul-2016.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Genexine | 15-Jul-2016 | PIPE | Biotechnology |
ProGen (Drug Discovery) ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Commercial Services
Industry
Rank
Percentile
Business Support Services
Subindustry
Rank
Percentile
ProGen (Drug Discovery) FAQs
-
When was ProGen (Drug Discovery) founded?
ProGen (Drug Discovery) was founded in 1998.
-
Where is ProGen (Drug Discovery) headquartered?
ProGen (Drug Discovery) is headquartered in Seoul, South Korea.
-
What is the size of ProGen (Drug Discovery)?
ProGen (Drug Discovery) has 50 total employees.
-
What industry is ProGen (Drug Discovery) in?
ProGen (Drug Discovery)’s primary industry is Drug Discovery.
-
Is ProGen (Drug Discovery) a private or public company?
ProGen (Drug Discovery) is a Public company.
-
What is ProGen (Drug Discovery)’s stock symbol?
The ticker symbol for ProGen (Drug Discovery) is 296160.
-
What is the current stock price of ProGen (Drug Discovery)?
As of 12-Nov-2026 the stock price of ProGen (Drug Discovery) is $1.35.
-
What is the current market cap of ProGen (Drug Discovery)?
The current market capitalization of ProGen (Drug Discovery) is $19.1M.
-
What is ProGen (Drug Discovery)’s current revenue?
The trailing twelve month revenue for ProGen (Drug Discovery) is $622K.
-
What is ProGen (Drug Discovery)’s annual earnings per share (EPS)?
ProGen (Drug Discovery)’s EPS for 12 months was -$0.98.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
